Viridian Therapeutics, Inc. (0K1R.L)
USD 13.68
(0.4%)
USD 13.68
(0.4%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -237.73 Million USD | -89.51% |
| 2022 | -125.44 Million USD | -57.96% |
| 2021 | -79.41 Million USD | 28.44% |
| 2020 | -110.98 Million USD | -161.63% |
| 2019 | -42.42 Million USD | -29.71% |
| 2018 | -32.7 Million USD | -23.35% |
| 2017 | -26.51 Million USD | -109.18% |
| 2016 | -12.67 Million USD | -11.88% |
| 2015 | -11.32 Million USD | -43.57% |
| 2014 | -7.89 Million USD | -265.33% |
| 2013 | -2.15 Million USD | 70.05% |
| 2012 | -7.21 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -48.54 Million USD | 27.4% |
| 2024 Q2 | -64.99 Million USD | -33.89% |
| 2023 Q2 | -55.06 Million USD | 19.08% |
| 2023 FY | -237.73 Million USD | -89.51% |
| 2023 Q3 | -47.66 Million USD | 13.44% |
| 2023 Q4 | -66.86 Million USD | -40.29% |
| 2023 Q1 | -68.04 Million USD | -60.09% |
| 2022 Q4 | -42.5 Million USD | -51.66% |
| 2022 Q2 | -29.49 Million USD | -15.66% |
| 2022 Q1 | -25.49 Million USD | 11.92% |
| 2022 FY | -125.44 Million USD | -57.96% |
| 2022 Q3 | -28.02 Million USD | 4.97% |
| 2021 Q2 | -17.96 Million USD | 2.69% |
| 2021 Q4 | -28.94 Million USD | -106.12% |
| 2021 FY | -79.41 Million USD | 28.44% |
| 2021 Q1 | -18.46 Million USD | 79.66% |
| 2021 Q3 | -14.04 Million USD | 21.83% |
| 2020 Q2 | -6.43 Million USD | 20.0% |
| 2020 Q3 | -5.49 Million USD | 14.62% |
| 2020 FY | -110.98 Million USD | -161.63% |
| 2020 Q4 | -90.74 Million USD | -1551.66% |
| 2020 Q1 | -8.04 Million USD | 20.5% |
| 2019 Q3 | -11.23 Million USD | -26.24% |
| 2019 Q1 | -11.62 Million USD | -12.72% |
| 2019 FY | -42.42 Million USD | -29.71% |
| 2019 Q4 | -10.11 Million USD | 9.9% |
| 2019 Q2 | -8.89 Million USD | 23.5% |
| 2018 FY | -32.7 Million USD | -23.35% |
| 2018 Q4 | -10.31 Million USD | -14.49% |
| 2018 Q3 | -9.01 Million USD | -3.41% |
| 2018 Q2 | -8.71 Million USD | -86.96% |
| 2018 Q1 | -4.66 Million USD | 27.01% |
| 2017 Q1 | -6.98 Million USD | -25.31% |
| 2017 Q2 | -7.31 Million USD | -4.76% |
| 2017 Q3 | -5.83 Million USD | 20.21% |
| 2017 Q4 | -6.38 Million USD | -9.46% |
| 2017 FY | -26.51 Million USD | -109.18% |
| 2016 FY | -12.67 Million USD | -11.88% |
| 2016 Q1 | -2.75 Million USD | 7.45% |
| 2016 Q2 | -2.5 Million USD | 9.1% |
| 2016 Q3 | -1.83 Million USD | 26.65% |
| 2016 Q4 | -5.57 Million USD | -202.88% |
| 2015 FY | -11.32 Million USD | -43.57% |
| 2015 Q4 | -2.98 Million USD | 5.46% |
| 2015 Q2 | -2.56 Million USD | 2.73% |
| 2015 Q1 | -2.63 Million USD | -16.65% |
| 2015 Q3 | -3.15 Million USD | -23.03% |
| 2014 Q4 | -2.25 Million USD | -37.92% |
| 2014 FY | -7.89 Million USD | -265.33% |
| 2014 Q1 | -705.77 Thousand USD | -247.35% |
| 2014 Q2 | -3.28 Million USD | -366.0% |
| 2014 Q3 | -1.63 Million USD | 50.22% |
| 2013 Q1 | -537.15 Thousand USD | 0.0% |
| 2013 FY | -2.15 Million USD | 70.05% |
| 2013 Q4 | -203.18 Thousand USD | 76.9% |
| 2013 Q3 | -879.63 Thousand USD | -62.99% |
| 2013 Q2 | -539.69 Thousand USD | -0.47% |
| 2012 FY | -7.21 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | -281.871% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | -15.812% |
| Codexis, Inc. | -76.24 Million USD | -211.823% |
| Organovo Holdings, Inc. | -14.67 Million USD | -1520.435% |